Avalon GloboCare Corp. (NASDAQ:ALBT) Short Interest Update

Avalon GloboCare Corp. (NASDAQ:ALBT) was the recipient of a large drop in short interest during the month of July. As of July 15th, there was short interest totalling 76,800 shares, a drop of 48.1% from the June 30th total of 148,000 shares. Based on an average daily trading volume, of 2,740,000 shares, the short-interest ratio is currently 0.0 days. Approximately 1.7% of the company’s shares are short sold.

Avalon GloboCare Trading Down 3.7 %

Shares of NASDAQ:ALBT opened at $0.40 on Friday. The stock’s 50-day moving average price is $0.46 and its two-hundred day moving average price is $0.39. Avalon GloboCare has a 12-month low of $0.24 and a 12-month high of $1.46. The firm has a market cap of $4.49 million, a price-to-earnings ratio of -0.29 and a beta of 0.32.

Avalon GloboCare (NASDAQ:ALBT) last issued its quarterly earnings results on Thursday, May 30th. The company reported ($0.12) earnings per share (EPS) for the quarter. The business had revenue of $0.32 million during the quarter.

Avalon GloboCare Company Profile

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and China. The company develops and delivers transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells.